$TWST

Officer at Twist Bioscience (TWST) preps 907-share sale

Twist Bioscience (TWST) officer Paula Green filed a Rule 144 notice to sell up to 907 shares, valued at $111K, following prior sales totaling 26,137 shares. The shares are tied to restricted stock vesting and include tax obligations. Sales were executed through Fidelity Brokerage Services on NASDAQ.

Original reporting
Published Sep 8, 2026, 7:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 10:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosed sale is modest; investors may view it as routine tax planning rather than a red flag.

02

Market read

Minor insider sale with limited price impact; primarily of interest to short‑term traders monitoring insider activity.

03

What to watch

Potential cumulative insider sales could become material if repeated over quarters.

Relevance 4/10Novelty 4/10Timing: filing Sep 8 2026

Background

Form 144 filings disclose planned sales of restricted securities by insiders before they become freely tradable.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Officer Paula Green filed a Rule 144 notice to sell up to 907 Twist Bioscience shares (~$111K).

Expected impact

minimal downward pressure, likely negligible

Evidence & confidence

Sale size is under $1M and represents a tiny fraction of float; market typically discounts such minor disposals.

Market effects

None

None

None

Counterpoint

If the insider is offloading shares for tax reasons, it may signal confidence rather than concern.

Key entities

  • Paula Green

    Twist Bioscience officer filing the Rule 144 notice.

  • Twist Bioscience Corp

    Biotech company listed on NASDAQ under ticker TWST.

Related articles

$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.

$TWSTMed

Why is Twist Bioscience stock rallying today?

Twist Bioscience (TWST) stock rose 3.7% after joining Eli Lilly's TuneLab platform as a preferred antibody data provider. The deal supports Twist's AI-driven life science strategy, following record Q3 revenue and raised guidance. The stock is near its 52-week high, with NASDAQ and S&P 500 also gaining.